These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

819 related items for PubMed ID: 22406880

  • 1. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [Abstract] [Full Text] [Related]

  • 2. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA, Lovato P, Cuesta G.
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K, Igoumenidis M, Karampli E, Vitsou E, Sykara G, Kyriopoulos J.
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [Abstract] [Full Text] [Related]

  • 4. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.
    Annemans L, Nackaerts K, Bartsch P, Prignot J, Marbaix S.
    Clin Drug Investig; 2009 Mar; 29(10):655-65. PubMed ID: 19715382
    [Abstract] [Full Text] [Related]

  • 6. Varenicline as compared to bupropion in smoking-cessation therapy--cost-utility results for Sweden 2003.
    Bolin K, Mörk AC, Willers S, Lindgren B.
    Respir Med; 2008 May; 102(5):699-710. PubMed ID: 18289839
    [Abstract] [Full Text] [Related]

  • 7. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D, Tappenden P, Peters J, Kenjegalieva K.
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of varenicline for smoking cessation.
    Keiding H.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):215-21. PubMed ID: 19527093
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H, Barendregt JJ.
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [Abstract] [Full Text] [Related]

  • 10. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K, Wilson K, Murphy D, Riesco JA.
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M, Welsing P, Rutten-van Mölken MP.
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [Abstract] [Full Text] [Related]

  • 12. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
    Wilson K, Hettle R, Marbaix S, Diaz Cerezo S, Ines M, Santoni L, Annemans L, Prignot J, Lopez de Sa E.
    Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
    [Abstract] [Full Text] [Related]

  • 13. Systematic review of the cost-effectiveness of varenicline vs. bupropion for smoking cessation.
    Mahmoudi M, Coleman CI, Sobieraj DM.
    Int J Clin Pract; 2012 Feb; 66(2):171-82. PubMed ID: 22257042
    [Abstract] [Full Text] [Related]

  • 14. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.
    Keating GM, Lyseng-Williamson KA.
    Pharmacoeconomics; 2010 Feb; 28(3):231-54. PubMed ID: 20108995
    [Abstract] [Full Text] [Related]

  • 15. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
    Vemer P, Rutten-van Mölken MP.
    Value Health; 2010 Feb; 13(2):230-41. PubMed ID: 19804435
    [Abstract] [Full Text] [Related]

  • 16. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
    Howard P, Knight C, Boler A, Baker C.
    Pharmacoeconomics; 2008 Feb; 26(6):497-511. PubMed ID: 18489200
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea.
    Bae JY, Kim CH, Lee EK.
    Value Health; 2009 Feb; 12 Suppl 3():S70-3. PubMed ID: 20586986
    [Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation.
    Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T.
    Addiction; 2011 Oct; 106(10):1819-26. PubMed ID: 21561499
    [Abstract] [Full Text] [Related]

  • 19. The cost-effectiveness of an extended course (12+12 weeks) of varenicline plus brief counselling compared with other reimbursed smoking cessation interventions in Belgium, from a public payer perspective.
    Knight C, Marbaix S, Annemans L, Prignot J, Bowrin K.
    Acta Clin Belg; 2012 Oct; 67(6):416-22. PubMed ID: 23340147
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries.
    Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, Aubin HJ.
    Eur J Public Health; 2009 Dec; 19(6):650-4. PubMed ID: 19491286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.